key: cord-0885388-3x5pfzau
authors: Qureshi, Adnan I.; Baskett, William I.; Huang, Wei; Ishfaq, Muhammad F.; Naqvi, S. Hasan; French, Brandi R.; Siddiq, Farhan; Gomez, Camilo R.; Shyu, Chi-Ren
title: Utilization and Outcomes of Acute Revascularization Treatment in Ischemic Stroke Patients with SARS-CoV-2 Infection
date: 2021-10-08
journal: J Stroke Cerebrovasc Dis
DOI: 10.1016/j.jstrokecerebrovasdis.2021.106157
sha: fbe5a3240829bed75460c2416a193c49c8c88cb1
doc_id: 885388
cord_uid: 3x5pfzau

OBJECTIVES: Acute ischemic stroke patients with severe acute respiratory syndrome coronavirus maybe candidates for acute revascularization treatments (intravenous thrombolysis and/or mechanical thrombectomy). MATERIALS AND METHODS: We analyzed the data from 62 healthcare facilities to determine the odds of receiving acute revascularization treatments in severe acute respiratory syndrome coronavirus infected patients and odds of composite of death and non-routine discharge with severe acute respiratory syndrome coronavirus infected and non-infected patients undergoing acute revascularization treatments after adjusting for potential confounders. RESULTS: Acute ischemic stroke patients with severe acute respiratory syndrome coronavirus infection were significantly less likely to receive acute revascularization treatments (odds ratio 0.6, 95% confidence interval 0.5-0.8, p=0.0001). Among ischemic stroke patients who received acute revascularization treatments, severe acute respiratory syndrome coronavirus infection was associated with increased odds of death or non-routine discharge (odds ratio 3.0, 95% confidence interval 1.8-5.1). The higher odds death or non-routine discharge (odds ratio 2.1, 95% confidence interval 1.9-2.3) with severe acute respiratory syndrome coronavirus infection were observed in all ischemic stroke patients without any modifying effect of acute revascularization treatments (interaction term for death (p=0.9) or death or non-routine discharge (p=0.2). CONCLUSIONS: Patients with acute ischemic stroke patients with severe acute respiratory syndrome coronavirus infection were significantly less likely to receive acute revascularization treatments. Severe acute respiratory syndrome coronavirus infection was associated with a significantly higher rate of death or non-routine discharge among acute ischemic stroke patients receiving revascularization treatments.

Our understanding of outcomes in acute ischemic stroke patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection following acute revascularization treatments (as intravenous thrombolysis and/or thrombectomy) is based on small case series. [1] [2] [3] . An international panel 4 cautioned regarding the potential for high rate of death or disability and post thrombolytic intracerebral hemorrhage (ICH)s in acute ischemic stroke patients with SARS-CoV-2 infection due to elevated concentrations of inflammation and hypercoagulability markers such as leukocytosis, and C reactive protein and D dimers and multisystem dysfunction. [4] [5] [6] [7] and recommended further studies to address these concerns. 4 We performed this analysis to understand utilization and associated outcomes of acute revascularization treatments in acute ischemic stroke patients with SARS-CoV-2 infection.

We analyzed the data from the Cerner de-identified COVID-19 dataset. 8 Our analysis included patients with prior medical history from the past 5 years to ensure completeness of the records of potential comorbidities which constituted approximately 76% of the total cohort. Patients in whom no previous medical encounter occurred during the past 5 years were excluded. Encounters with missing data for certain non-essential variables such as gender were included.

In general, the Cerner de-identified COVID-19 dataset comprise more than 100 clinical and nonclinical variables associated with hospital stays, including primary and secondary diagnoses, primary and secondary procedures, patients' admission and discharge status, and patient demographic information. Cerner Corporation has established Health Insurance Portability and Accountability Act-compliant operating policies to establish de-identification for Cerner Real-World Data.

(ICD-10-CM) primary diagnosis codes I63, I65 and I66 to identify the patients admitted with acute ischemic stroke. We also used ICD-10 procedure codes to estimate the proportion of patients who underwent mechanical thrombectomy (03CG3ZZ, 03CG3Z7, 03CH3Z7, 03CJ0ZZ, 03CJ3ZZ, 03CK3Z7, 03CK3ZZ, 03CL3Z7, 03CL3ZZ, 03CL0ZZ, 03CP3ZZ, 03CY3ZZ, 00C73ZZ) and/or intravenous thrombolysis administration (3E03317 and 3E06317). The ICD-10-CM codes were also used to identify the patients with other medical co-morbidities and in-hospital events. 9 : hypertension (I10, O10.0, O10.9, I16 and I67.4), diabetes mellitus (E08, E09, E10, E11 and E13), atrial fibrillation (I48), hyperlipidemia (E78), malignancy (Z85), nicotine dependence (F17), The primary outcome was in-hospital death. The secondary outcome was a composite of death or non-routine discharge (discharge to destinations other than home, such as short-term hospitals or other facilities including intermediate care and skilled nursing homes).

We performed a logistic regression analysis including all ischemic stroke patients to identify the odds of receiving acute revascularization treatments in the presence of SARS-CoV-2 infection after adjusting for age (age strata), gender, race/ethnicity, hypertension, diabetes mellitus, atrial fibrillation, hyperlipidemia, malignancy, nicotine dependence, previous ischemic stroke, previous subarachnoid hemorrhage, previous ICH, previous acute myocardial infarction, previous transient cerebral ischemic attack, congestive heart failure, peripheral vascular disease, deep venous thrombosis, or previous pulmonary embolism.

We performed four logistic regression analyses to determine the independent effect of SARS-CoV-2 infection on 1/. death and 2/. death or non-routine discharge. Analysis 1 and 2 included patients who underwent acute revascularization treatments and analysis 3 and 4 included all acute ischemic stroke patients. Potential confounders included age (age strata), gender, race/ethnicity, hypertension, diabetes mellitus, atrial fibrillation, hyperlipidemia, malignancy, nicotine dependence, previous ischemic stroke, previous subarachnoid hemorrhage, previous ICH, previous acute myocardial infarction, previous transient cerebral ischemic attack, congestive heart failure, peripheral vascular disease, deep venous thrombosis, previous pulmonary embolism. We entered use of acute revascularization treatments as an interaction term in analysis 3 and 4. Any p-values less than 0.05 are considered significant. All the analyses were done using R (version 3.6.1).

The proportions of men, African American, and Hispanic, and patients with diabetes mellitus, previous subarachnoid hemorrhage, congestive heart failure and deep venous thrombosis were significantly higher among those with SARS-CoV-2 infection (see Table 1 ). The in-hospital mortality (21.4% versus 7.0%, p<0.0001) and non-routine discharges (76.1% versus 60.4%, p<0.0001) were higher among acute ischemic stroke patients with SARS-CoV-2 infection than in those without SARS-CoV-2 infection (see Table 1 ).

The proportions of patients who received acute revascularization treatments among acute ischemic stroke patients with SARS-CoV-2 infection were lower than those without SARS-CoV-2 infection (4.5% versus 7.1%, p<0.0001). Among ischemic stroke patients, 55(2.6%) and 751 (3.4%) received intravenous thrombolysis only, 35 (1.6%) and 729 (3.8%) received mechanical thrombectomy only, and 6 (0.3%) and 108 (0.5%) received both, in patients with and without SARS-CoV-2 infection, respectively. Patients with SARS-CoV-2 infection were significantly less likely to receive acute revascularization treatment among patients with ischemic stroke (odds ratio [OR] 0.6, 95% confidence interval [CI] 0.5-0.8, p=0.0001). Other factors associated with receiving receive acute revascularization treatment were African American race (OR 0.6, 95% CI 0.6-0.8, p<0.0001), diabetes mellitus (OR 0.7, 95% CI 0.7-0.8, p<0.0001), malignancy (OR 0.8, 95% CI 0.7-1.0, p=0.01), previous subarachnoid hemorrhage (OR 0.5, 95% CI 0.3-0.9, p=0.02), congestive heart failure (OR 0.8, 95% CI 0.7-0.9, p=0.002), and peripheral vascular disease (OR 0.8, 95% CI 0.7-0.9, p=0.001).

Patients with SARS-CoV-2 infection who received acute revascularization treatment were more likely to have pneumonia, respiratory failure, AKI, septic shock, cardiac arrest, and require intubation/mechanical ventilation. The proportion of patients who died during hospitalization (21.9% versus 6.5%, p<0.0001) and those with non-routine discharge (79.2% versus 56.4%, p<0.0001) were significantly higher among patients with SARS-CoV-2 infection compared with those without SARS-CoV-2 infection (See Table 1 ). The proportion of patients who experienced subarachnoid hemorrhage (1% versus 0.6%) or ICH (2.1% versus 1.4%) were similar between patients with and without SARS-CoV-2 infection.

Among all ischemic stroke patients who received acute revascularization treatments, SARS-CoV-2 infection was associated with increased odds of death (OR 4.1, 95% CI 2.3-7.2) (see Table 2 ) and death or non-routine discharge (OR 3.0, 95% CI 1.8-5.1) (see Table 2 ) after adjusting for potential confounders.

SARS-CoV-2 infection was associated with increased odds of death (OR 3.4, 95% CI 3.0-3.9) (see Table 2 ) and death or non-routine discharge (OR 2.1, 95% CI 1.9-2.3) (see Table 2 ) after adjusting for potential confounders. Utilization of acute revascularization treatments was not associated with significantly higher odds of death (OR 1.0, 95% CI 0.8-1.2) (see Table 2 ) and death or non-routine discharge (OR 0.9, 95% CI 0.8-1.0) (see Table 2 ). The interaction term between SARS-CoV-2 infection and acute revascularization treatments was not significant for either death (p=0.9) or death or non-routine discharge (p=0.2) in the multivariate model.

Patients who have acute ischemic stroke with SARS-CoV-2 infection are significantly less likely to receive acute revascularization treatments even though SARS-CoV-2 infection is not considered a contraindication for such treatments. 4, 15 Current guidelines recommend prompt revascularization treatments during the current pandemic because of the high mortality rate and severe neurological disability in untreated patients. [16] [17] [18] Several studies have reported a reduction in rates of utilization of acute revascularization treatments, and increase in time to treatment among acute ischemic stroke patients during the SARS-CoV-2 infection pandemic. [19] [20] [21] [22] A relative reduction in number of mechanical thrombectomy procedures performed during the pandemic has been reported ranging from 21% in France, 25.3% in China, and 33% in in New York city compared with the procedures performed before the SARS-CoV-2 infection pandemic. 16, 21, 23 An international study from 11 institutions from the United States and 7 international institutions found 8% reduction in mechanical thrombectomy procedures between 2019 and 2020, which was more prominent in regions with high prevalence of SARS-CoV-2 infection. 22 Another study from 187 comprehensive stroke centers. 24 The restricted use of acute revascularization treatments in SARS-CoV-2 infected patients may be due to increased delays from stroke onset to treatment consideration. 16, 21, 23 attributed to screening and preventive strategies to reduce transmission 25 in initial evaluation, and performance of neuroimaging, and mechanical thrombectomy. There may be reluctance in using acute revascularization treatments due to presence of elevated concentration of inflammation and hypercoagulability markers 4,6,7 and reports of high mortality in patients with SARS-CoV-2 infection who were treated with acute revascularization treatments. 1-3 Patients with SARS-CoV-2 infection may be excluded due to hepatic dysfunction 5 and coagulopathy (elevated prothrombin time, international normalized ratio, activated partial thromboplastin time, or reduced platelet count). The relatively high rate of renal insufficiency with subsequent acute kidney injury in patients with SARS-CoV-2 infection 26 may delay or preclude administration of contrast for computed tomography angiography and/or perfusion to identify appropriate candidates.

Among patients who received acute revascularization treatment, patients with SARS-CoV-2 infection had significantly higher adjusted odds for in hospital death (OR 4.1) and also for death and non-routine discharge (OR 3.0). However, the higher rates for in hospital death and also for non-routine discharge were also seen in SARS-CoV-2 infected patients in overall cohort of acute ischemic stroke patients suggesting no unique effect of acute revascularize treatments. These adverse outcomes are related to higher rates of pneumonia, respiratory failure, AKI, septic shock, cardiac arrest, and requirement for intubation/mechanical ventilation in SARS-CoV-2 infected ischemic stroke patients. We did not see any modifying effect (interaction term p>0.05) of acute revascularization treatments in the relationship between SARS-CoV-2 infection and in hospital death or composite endpoint of death and non-routine discharge. The proportions of patients with post-treatment ICH or subarachnoid hemorrhage were similar in patients with and without SARS-CoV-2 infection receiving acute revascularization treatments.

Our results do not support withholding acute revascularization treatments in SARS-CoV-2 infected patients as we did not identify any higher risk of post treatment ICH or subarachnoid hemorrhage. However, the outcome of patients with SARS-CoV-2 infection and ischemic stroke is probably determined by the severity of multi-organ dysfunction and may obscure some or all of the benefit of acute revascularization treatments. An international panel 4 recommended assessment of the magnitude of organ dysfunction using Sequential Organ Failure Assessment score 27 to delineate the overall care paradigm in acute stroke patients in accord with the expected prognosis. Other factors such as older age, cardiovascular diseases, secondary infections, acute respiratory distress syndrome, acute renal injury and laboratory findings of lymphopenia and elevated hepatic enzymes, and inflammatory markers associated with increased mortality may have to considered at time of decision making. [28] [29] [30] Limitations We used Cerner de-identified COVID-19 dataset 9,14 which provides minimal details on the time interval between symptom onset to arrival, severity of neurological deficits, and diagnostic study results (neuroimaging and laboratory tests), or the exact reasons for exclusion from acute revascularization treatments. There is probably a selection bias towards inclusion of patients with greater severity of symptoms by limiting the analysis to emergency department and hospitalized patients. The dataset also depends on the accuracy of diagnosis and procedures codes. ICD-10 diagnosis codes have a high positive predictive value to identify acute ischemic stroke from the principle discharge diagnosis. 31 The ICD-10 codes can identify 98% of all patients receiving intravenous thrombolysis and 87% of all patients receiving mechanical thrombectomy. 32 The discharge functional outcome cannot be measured with the available data, and the closest index was using the destination of discharge as done in previous studies using Nationwide Inpatient Sample data. 33, 34 Conclusions Patients with acute ischemic stroke patients with SARS-CoV-2 infection were significantly less likely to receive acute revascularization treatments and had higher rates of death or non-routine discharge regardless of use of acute revascularization treatments. 

A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients

Thrombolysis and bridging therapy in patients with acute ischaemic stroke and Covid-19

Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: Experience from paris

Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel

Clinical characteristics of coronavirus disease 2019 in China

Stroke Thrombolysis Registry G. Body temperature, blood infection parameters, and outcome of thrombolysis-treated ischemic stroke patients

High plasma D-dimer indicates unfavorable outcome of acute ischemic stroke patients receiving intravenous thrombolysis

Cerner provides access to de-identified patient data for COVID-19 research and vaccine development

Facilitating the study of relationships between COVID-19 and cardiovascular health outcomes using cerner Real-World COVID-19 deidentified dataset

Re-infection with SARS-CoV-2 in patients undergoing serial laboratory testing

Subarachnoid hemorrhage and COVID-19: An analysis of 282,718 patients

Effect of race and ethnicity on in-hospital mortality in patients with COVID-19

Acute ischemic stroke and COVID-19: An analysis of 27 676 patients

Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the

Acute stroke management during the COVID-19 pandemic: Does confinement impact eligibility for endovascular therapy?

European Stroke Organisation (ESO) -European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischaemic strokeendorsed by Stroke Alliance for Europe (SAFE)

Temporary emergency guidance to US stroke centers during the coronavirus disease 2019 (COVID-19) pandemic: On behalf of the American Heart Association/American Stroke Association stroke council leadership

Intravenous thrombolysis for acute ischaemic stroke during COVID-19 pandemic in Wuhan, China: a multicentre, retrospective cohort study

Influence of the COVID-19 Pandemic on Treatment Times for Acute Ischemic Stroke: The Society of Vascular and Interventional Neurology Multicenter Collaboration

Impact of the COVID-19 epidemic on stroke care and ootential solutions

Changes in neuroendovascular procedural volume during the COVID-19 pandemic: An international multicenter study

Mechanical thrombectomy for acute ischemic stroke amid the COVID-19 outbreak: Decreased activity, and increased care delays

Global impact of COVID-19 on stroke care

Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)

Kidney disease is associated with in-hospital death of patients with COVID-19

The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Validation of acute ischemic stroke codes using the international classification of diseases tenth revision

Strategy for reliable identification of ischaemic stroke, thrombolytics and thrombectomy in large administrative databases

National trends in utilization and outcomes of endovascular treatment of acute ischemic stroke patients in the mechanical thrombectomy era

Discharge destination as a surrogate for Modified Rankin Scale defined outcomes at 3-and 12-months poststroke among stroke survivors